Origins and impact of extrachromosomal DNA
['Bailey, Chris', 'Jamal-Hanjani, Mariam', 'Swanton, Charles']; Nature; 2024年11月1日
『Abstract』Extrachromosomal DNA (ecDNA) is a major contributor to treatment resistance and poor outcome for patients with cancer. Here we examine the diversity of ecDNA elements across cancer, revealing the associated tissue, genetic and mutational contexts. By analysing data from 14,778 patients with 39 tumour types from the 100,000 Genomes Project, we demonstrate that 17.1% of tumour samples contain ecDNA. We reveal a pattern highly indicative of tissue-context-based selection for ecDNAs, linking their genomic content to their tissue of origin. We show that not only is ecDNA a mechanism for amplification of driver oncogenes, but it also a mechanism that frequently amplifies immunomodulatory and inflammatory genes, such as those that modulate lymphocyte-mediated immunity and immune effector processes. Moreover, ecDNAs carrying immunomodulatory genes are associated with reduced tumour T cell infiltration. We identify ecDNAs bearing only enhancers, promoters and lncRNA elements, suggesting the combinatorial power of interactions between ecDNAs in trans . We also identify intrinsic and environmental mutational processes linked to ecDNA, including those linked to its formation, such as tobacco exposure, and progression, such as homologous recombination repair deficiency. Clinically, ecDNA detection was associated with tumour stage, more prevalent after targeted therapy and cytotoxic treatments, and associated with metastases and shorter overall survival. These results shed light on why ecDNA is a substantial clinical problem that can cooperatively drive tumour growth signals, alter transcriptional landscapes and suppress the immune system.
『摘要』
外染色体DNA(ecDNA)是癌症治疗抗性和不良预后的主要原因。本文我们探讨了ecDNA在癌症中的多样性,揭示了其与相关组织、基因和突变背景的关联。通过分析来自《100,000基因组计划》项目的14,778名癌症患者、39种肿瘤类型的数据,我们证实了17.1%的肿瘤样本含有ecDNA。我们发现了一个高度指示组织背景选择性分布的模式,将ecDNA的基因组内容与其来源组织相关联。我们的研究表明,ecDNA不仅是驱动致癌基因扩增的机制,还经常扩增免疫调节基因和炎症基因,如调节淋巴细胞介导免疫和免疫效应过程的基因。此外,携带免疫调节基因的ecDNA与肿瘤T细胞浸润减少有关。我们还鉴定出了仅携带增强子、启动子和lncRNA(长链非编码 RNA)元件的ecDNA,表明ecDNA之间的交互作用具有组合性效应。此外,我们还识别出了与ecDNA相关的内在和环境导致的突变过程,包括其形成相关(如烟草暴露)和进展相关(如同源重组修复缺陷)的过程。临床上,ecDNA检测与肿瘤分期相关,在靶向治疗和细胞毒治疗后更为普遍,并且与癌症转移和较短的总生存期相关。这些结果揭示了为什么ecDNA是一个实质性的临床问题——可以协同驱动肿瘤生长信号、改变转录格局和抑制免疫系统。
『总结』
研究发现外染色体DNA(ecDNA)是癌症治疗抵抗和不良预后的主要贡献者,ecDNA可以扩增致癌基因、免疫调节基因,并抑制免疫系统。
【闲叙】
None